The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies

Dong, Yanzhao; Zhou, Haiying; Alhaskawi, Ahmad; Wang, Zewei; Lai, Jingtian; Yao, Chengjun; Liu, Zhongfan; Ezzi, Sohaib Hasan Abdullah; Kota, Vishnu Goutham; Abdulla, Mohamed Hasan Abdulla Hasan; Lü, Hui

doi:10.3390/cancers15041193

Cited by 11 publications

(12 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FAPi is characterized by high intratumoral uptake and rapid in vivo clearance. Various types of FAPi have since been developed and compared head-to-head with fluorodeoxyglucose (FDG) PET-CT, showing that FAPi tracers are more advantageous in discovering some primary, lymph node, or metastatic tumors (112,115,117). However, the sample sizes of these studies are very limited and there is still no convincing evidence of which tumor types or which metastatic organs are more appropriate to FAPi.…”

Section: Differential Expression Levels Of Biomarkers In Pcafs and Mcafsmentioning

confidence: 99%

Heterogeneity of primary and metastatic CAFs: From differential treatment outcomes to treatment opportunities (Review)

Kou,

Liu,

Zhang

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

Compared with primary tumor sites, metastatic sites appear more resistant to treatments and respond differently to the treatment regimen. It may be due to the heterogeneity in the microenvironment between metastatic sites and primary tumors. Cancer-associated fibroblasts (CAFs) are widely present in the tumor stroma as key components of the tumor microenvironment. Primary tumor CAFs (pCAFs) and metastatic CAFs (mCAFs) are heterogeneous in terms of source, activation mode, markers and functional phenotypes. They can shape the tumor microenvironment according to organ, showing heterogeneity between primary tumors and metastases, which may affect the sensitivity of these sites to treatment. It was hypothesized that understanding the heterogeneity between pCAFs and mCAFs can provide a glimpse into the difference in treatment outcomes, providing new ideas for improving the rate of metastasis control in various cancers. Contents 1. Introduction 2. Heterogeneity of mCAFs and pCAFs 3. Differential therapeutic response mediated by pCAFs and mCAFs 4. Potential therapeutic opportunities targeting mCAFs 5. Conclusion

show abstract

Section: Differential Expression Levels Of Biomarkers In Pcafs and Mcafsmentioning

confidence: 99%

Heterogeneity of primary and metastatic CAFs: From differential treatment outcomes to treatment opportunities (Review)

Kou,

Liu,

Zhang

et al. 2024

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…FAP is highly expressed by CAFs, and 90% of epithelial tumors and metastases are positive; meanwhile, it is absent in normal adult tissues [97][98][99]. The presence of CAFs and FAP expression have been reported to be strongly associated with metastasis and poor prognosis in various tumor types, making FAP a suitable target for tumor imaging and therapy [100,101]. Recently, several clinical trials were performed using FAP inhibitors (FAPIs) or FAP-targeted antibodies labeled with 68 Ga or 18 F for PET imaging and have been recently described in detail by Huang et al [102].…”

Section: Development Of 18 F-psma-1007 For Imagingmentioning

confidence: 99%

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Echavidre,

Fagret,

Faraggi

et al. 2023

Cancers

View full text Add to dashboard Cite

The theranostic approach in oncology holds significant importance in personalized medicine and stands as an exciting field of molecular medicine. Significant achievements have been made in this field in recent decades, particularly in treating neuroendocrine tumors using 177-Lu-radiolabeled somatostatin analogs and, more recently, in addressing prostate cancer through prostate-specific-membrane-antigen targeted radionuclide therapy. The promising clinical results obtained in these indications paved the way for the further development of this approach. With the continuous discovery of new molecular players in tumorigenesis, the development of novel radiopharmaceuticals, and the potential combination of theranostics agents with immunotherapy, nuclear medicine is poised for significant advancements. The strategy of theranostics in oncology can be categorized into (1) repurposing nuclear medicine agents for other indications, (2) improving existing radiopharmaceuticals, and (3) developing new theranostics agents for tumor-specific antigens. In this review, we provide an overview of theranostic development and shed light on its potential integration into combined treatment strategies.

show abstract

“…In recent years, a new PET imaging model, FAPI PET, has been developed using FAP-speci c inhibitors. It has been observed that 68 Ga-FAPI PET/CT has higher SUVmax values than 18 FDGPET/CT in various cancer types (4,5). Additionally, it has been observed that 68 Ga-FAPI PET/CT is more successful in lobular breast cancer(6), mucinous colon cancer, and signet cell gastric cancer, where 18 FDGPET/CT is insu cient (7,8).…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of 68Ga-FAPI-PET/CT in patients with bone metastases in various cancers

ARAK,

Elboga,

Cayırlı

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective:This study aimed to compare and18FDGPET/CT in patients who develop bone metastases due to various cancers and to investigate the prognostic significance of the 68FAPI-PET/CT SUVmax value for survival. Methods:Patients with bone metastases who underwent both 68Ga-FAPI PET/CTand18FDGPET/CT within a 1-week period were included in this retrospective study. The effect of the SUVmax value of bone lesions on overall survival was analyzed. Results:A total of 75 eligible patients with 139 bone lesions were included in this study. The median age of the patients was 55(30–83) and 48 patients (64%) were newly diagnosed. The primary lesion median 68Ga-FAPI PET/CT SUVmax value was higher than the median 18FDGPET/CT SUVmax (10.75 versus 6.7). Bone lesions 68Ga-FAPI PET/CT SUVmax median(IQR) were 7.8(4.6–13.2), and 18FDGPET/CT SUVmax of bone lesions were 5.9(3.8–8.2). More bone lesions were detected on 68Ga-FAPI PET/CT than on 18FDGPET/CT(median IQR 4 [1–9] versus 2 [1–6](p=0.014). The extra lesions observed on 68Ga-FAPI PET/CT were mostly sclerotic bone lesions(p = 0.001).68Ga-FAPI PET/CT SUVmax was significantly higher in vertebra and thorax lesions(p=0.011 and p=0.018, respectively). While the bone lesion 68Ga-FAPI PET/CT SUVmax affected the OS, the 18FDGPET/CT SUVmax value did not affect the OS (p<0.001 and p=0.079, respectively). In ROC analysis, a cut-off value of 68Ga-FAPI PET/CT SUVmax >7.7 was found for OS(AUC:0.619). The median OS in the group above the cut-off value was worse than that in the group below the cut-off value (32 versus 45) months (p=0.002). In the multivariate analysis for OS, the 68Ga-FAPI PET/CT SUVmax of bone lesions was an important parameter,as well as cancer subtype, ALP level, and disease occurrence. Conclusions:68Ga-FAPI PET/CT detected more bone lesions and higher SUVmax values than 18FDGPET/CT in various cancers. The prognostic value of the SUVmax value of 68Ga-FAPI PET/CT bone lesions was observed regardless of disease subtype.

show abstract

The Superiority of Fibroblast Activation Protein Inhibitor (FAPI) PET/CT Versus FDG PET/CT in the Diagnosis of Various Malignancies

Cited by 11 publications

References 123 publications

Heterogeneity of primary and metastatic CAFs: From differential treatment outcomes to treatment opportunities (Review)

Heterogeneity of primary and metastatic CAFs: From differential treatment outcomes to treatment opportunities (Review)

Recent Pre-Clinical Advancements in Nuclear Medicine: Pioneering the Path to a Limitless Future

Prognostic significance of 68Ga-FAPI-PET/CT in patients with bone metastases in various cancers

Contact Info

Product

Resources

About